It seems clear that the performance of Zenakine is the only thing keeping the sp in double figures as the rest of the portfolio has been a big disappointment. I would be interested to see how Ashman explains this on the expected podcast.
These 'pie in the sky' broker notes with absurd target prices need to have some sort of results based health (or wealth) warnings attached.
How often has the analyst in question reached the target price with his forecasts? If it is less than 20% then we can safely dismiss the research as 'living in dreamland'. Navigating the cesspit known as AIM is hard enough without these clowns giving us false hopes.
That's good news Add. Of course, the secondary reason they are buying now is that there's ample liquidity at the moment. If they didn't think they'd be able to buy a reasonable quantity of shares (and be able to sell them again) without affecting the price then they probably wouldn't have gone ahead with the purchase
I believe that Willem Middlekoop's Commodity Discovery Fund also has a holding but I don't know what %age. He has certainly spoken about SOLG in previous podcasts...
Personally I am quite surprised that the sp is not above 30p already, reflecting the likelihood of higher bids to come. The chances must be greater than 50/50 and yet we are only 10% higher than the rejected Jiangxi bid...